Cerebrospinal fluid oligoclonal IgM bands predict early conversion to clinically definite multiple sclerosis in patients with Clinically Isolated Syndrome

Journal of Neuroimmunology

Volumn 257, Issue 1-2, 2013, Pages 76-81

  Ferraro, Diana ^a,b   Simone, Anna Maria ^a   Bedin, Roberta ^a   Galli, Veronica ^a   Vitetta, Francesca ^a   Federzoni, Lucia ^a   D'amico, Roberto ^a   Merelli, Elisa ^a   Nichelli, Paolo Frigio ^a   Sola, Patrizia ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b Nuovo Ospedale S Agostino   (Italy)

Author keywords

Cerebrospinal fluid; Clinically Isolated Syndrome; Immunoglobulin M; Multiple sclerosis; Oligoclonal bands

Indexed keywords

IMMUNOGLOBULIN M; OLIGOCLONAL BAND;

ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE;

ADULT; BIOLOGICAL MARKERS; DEMYELINATING DISEASES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN M; MALE; MULTIPLE SCLEROSIS; OLIGOCLONAL BANDS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SPINAL PUNCTURE; YOUNG ADULT;

EID: 84875805250     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.01.011     Document Type: Article

References (42)

1. Boscá I., Magraner M.J., Coret F., Alvarez-Cermeño J.C., Simó-Castelló M., Villar L.M., Casanova B. The risk of relapse after a clinically isolated syndrome is related to the pattern of oligoclonal bands. J. Neuroimmunol. 2010, 226:143-146.
2. Brex P.A., Ciccarelli O., Jonathon I., O'Riordan J.I., Sailer M., Thompson A.J., Miller D.H. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N. Engl. J. Med. 2002, 346:158-164.
3. Comi G., Filippi M., Barkhof F., Durelli L., Edan G., Fernández O., Hartung H., Seeldrayers P., Sørensen P.S., Rovaris M., Martinelli V., Hommes O.R. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001, 357:1576-1582.
4. Comi G., Martinelli V., Rodegher M., Moiola L., Bajenaru O., Carra A., Elovaara I., Fazekas F., Hartung H.P., Hillert J., King J., Komoly S., Lubetzki C., Montalban X., Myhr K.M., Ravnborg M., Rieckmann P., Wynn D., Young C., Filippi M. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome PreCISe study: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 374:1503-1511.
5. Confavreux C., Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006, 129:606-616.
6. Durante L., Zaaraoui W., Rico A., Crespy L., Wybrecht D., Faivre A., Reuter F., Malikova I., Pommier G., Confort-Gouny S., Cozzone P.J., Ranjeva J.P., Pelletier J., Boucraut J., Audoin B. Intrathecal synthesis of IgM measured after a first demyelinating event suggestive of multiple sclerosis is associated with subsequent MRI brain lesion accrual. Mult. Scler. 2012, 18:587-592.
7. Fisniku L.K., Brex P., Altmann D.R., Miszkiel K., Benton C.E., Lanyon R., Thompson A.J., Miller D.H. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008, 131:808-817.
8. García-Barragán N., Villar L.M., Espiño M., Sádaba M.C., González-Porqué P., Alvarez-Cermeño J.C. Multiple sclerosis patients with anti-lipid oligoclonal IgM show early favourable response to immunomodulatory treatment. Eur. J. Neurol. 2009, 16:380-385.
9. Gout O., Bouchareine A., Moulignier A., Deschamps R., Papeix C., Gorochov G., Héran F., Bastuji-Garin S. Prognostic value of cerebrospinal fluid analysis at the time of a first demyelinating event. Mult. Scler. 2011, 17:164-172.
10. Jacobs L.D., Beck R.W., Simon J.H., Kinkel R.P., Brownscheidle C.M., Murray T.J., Simonian N.A., Slasor P.J., Sandrock A.W. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med. 2000, 343:898-904.
11. Jacobs L.D., Beck R.W., Simon J.H., Kinkel R.P., Brownscheidle C.M., Murray T.J., Simonian N.A., Slasor P.J., Sandrock A.W. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. Am. J. Ophthalmol. 2001, 131:154-155. the CHAMPS Study Group.
12. Jongen P.J.H., Lycklama a Nijeholt G., Lamers K.J.B., Doesburg W.H., Barkhof F., Lemmens W.A.J.G., Klasen I.S., Hommes O.R. Cerebrospinal fluid IgM index correlates with cranial MRI lesion load in patients with multiple sclerosis. Eur. Neurol. 2007, 58:90-95.
13. Kappos L., Polman C.H., Freedman M.S., Edan G., Hartung H.P., Miller D.H., Montalban X., Barkhof F., Bauer L., Jakobs P., Pohl C., Sandbrink R. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006, 67:1242-1249.
14. Kurtzke J.F., Beebe G.W., Nagler B., Kurland L.T., Auth T.L. Studies on the natural history of multiple sclerosis - 8. Early prognostic features of the later course of the illness. J. Chronobiol. Dis. 1977, 30:819-830.
15. Leray E., Yaouanq J., Le Page E., Coustans M., Laplaud D., Oger J., Edan G. Evidence for a two-stage disability progression in multiple sclerosis. Brain 2010, 133:1900-1913.
16. Magraner M.J., Bosca I., Simó-Castelló M., García-Martí G., Alberich-Bayarri A., Coret F., Alvarez-Cermeño J.C., Martí-Bonmatí L., Villar L.M., Casanova B. Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes. Neuroradiology 2012, 54:5-12.
17. Mandrioli J., Sola P., Bedin R., Gambini M., Merelli E. A multifactorial prognostic index in multiple sclerosis. Cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease. J. Neurol. 2008, 255:1023-1031.
18. Mead R.J., Singhrao S.K., Neal J.W., Lassmann H., Morgan B.P. The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. J. Immunol. 2002, 168:458-465.
19. Miller D.H., Chard D.T., Ciccarelli O. Clinically isolated syndromes. Lancet Neurol. 2012, 11:157-169.
20. Morrissey S.P., Miller D.H., Kendall B.E., Kingsley D.P., Kelly M.A., Francis D.A., MacManus D.G., McDonald W.I. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain 1993, 116:135-146.
21. Mowry E.M., Pesic M., Grimes B., Deen S.R., Bacchetti P., Waubant E. Clinical predictors of early second event in patients with clinically isolated syndrome. J. Neurol. 2009, 256:1061-1066.
22. O'Riordan J.I., Thompson A.J., Kingsley D.P.E., MacManus D.G., Kendall B.E., Rudge P., McDonald W.I., Miller D.H. The prognostic value of brain MRI in clinically isolated syndromes of the CNS: a 10year follow-up. Brain 1998, 121:495-503.
23. Optic Neuritis Study group Multiple sclerosis risk after optic neuritis. Brain 2008, 65:727-732.
24. Perini P., Ranzato F., Calabrese M., Battistin L., Gallo P. Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2006, 77:953-955.
25. Polman C., Kappos L., Freedman M.S., Edan G., Hartung H.P., Miller D.H., Montalbán X., Barkhof F., Selmaj K., Uitdehaag B.M.J., Dahms S., Bauer L., Pohl C., Sandbrink R. Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b. J. Neurol. 2008, 255:480-487.
26. Rosenbluth J., Schiff R., Liang W.L., Dou W.K., Moon D. Antibody-mediated CNS demyelination: focal spinal cord lesions induced by implantation of an IgM anti-galactocerebroside-secreting hybridoma. J. Neurocytol. 1999, 28:397-416.
27. Rosenbluth J., Schiff R., Liang W.L., Dou W. Antibody-mediated CNS demyelination II. Focal spinal cord lesions induced by implantation of an IgM antisulfatide-secreting hybridoma. J. Neurocytol. 2003, 32:265-276.
28. Ruet A., Deloire M.S., Ouallet J.C., Molinier S., Brochet B. Predictive factors for multiple sclerosis in patients with clinically isolated spinal cord syndrome. Mult. Scler. 2011, 17:312-318.
29. Scalfari A., Neuhaus A., Degenhardt A., Rice G.P., Muraro P., Daumer M., Ebers G.C. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 2010, 133:1914-1929.
30. Sindic C.J., Monteyne P., Laterre E.C. Occurrence of oligoclonal IgM bands in the cerebrospinal fluid of neurological patients: an immunoaffinity-mediated capillary blot study. J. Neurol. Sci. 1994, 124:215-219.
31. Sola P., Mandrioli J., Simone A.M., Ferraro D., Bedin R., Annecca R., Venneri M.G., Nichelli P.F., Merelli E. Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM. Mult. Scler. 2011, 17:303-311.
32. Swanton J.K., Fernando K., Dalton C.M., Miszkiel K.A., Thompson A.J., Plant G.T., Miller D.H. Is the frequency of abnormalities on magnetic resonance imaging in isolated optic neuritis related to the prevalence of multiple sclerosis? A global comparison. J. Neurol. Neurosurg. Psychiatry 2006, 77:1070-1072.
33. Thangarajh M., Gomez-Rial J., Hedström K., Hillert J., Alvarez-Cermeño J.C., Masterman T., Villar L.M. Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis. Mult. Scler. 2008, 14:1208-1213.
34. Tintoré M., Rovira A., Rio J., Nos C., Grivé E., Téllez N., Pelayo R., Comabella M., Montalban X. Is optic neuritis more benign than other first attacks in multiple sclerosis?. Ann. Neurol. 2005, 57:210-215.
35. Tintoré M., Rovira A., Río J., Nos C., Grivé E., Téllez N., Pelayo R., Comabella M., Sastre-Garriga J., Montalban X. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006, 67:968-972.
36. Tintoré M., Rovira A., Río J., Tur C., Pelayo R., Nos C., Téllez N., Perkal H., Comabella M., Sastre-Garriga J., Montalban X. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?. Neurology 2008, 70:1079-1083.
37. Villar L.M., González-Porqué P., Masjuán J., Alvarez-Cermeño J.C., Bootello A., Keir G. A sensitive and reproducible method for the detection of oligoclonal IgM bands. J. Immunol. Methods 2001, 258:151-155.
38. Villar L.M., Masjuan J., González-Porqué P., Plaza J., Sádaba M.C., Roldán E., Bootello A., Alvarez-Cermeño J.C. Intrathecal IgM synthesis in neurologic diseases: relationship with disability in MS. Neurology 2002, 58:824-826.
39. Villar L.M., Masjuan J., González-Porqué P., Plaza J., Sádaba M.C., Roldán E., Bootello A., Alvarez-Cermeño J.C. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology 2002, 59:555-559.
40. Villar L.M., Masjuan J., González-Porqué P., Plaza J., Sádaba M.C., Roldán E., Bootello A., Alvarez-Cermeño J.C. Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann. Neurol. 2003, 53:222-226.
41. Villar L.M., Sádaba M.C., Roldán E., Masjuan J., González-Porqué P., Villarrubia N., Espiño M., García-Trujillo J.A., Bootello A. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J. Clin. Invest. 2005, 115:187-194.
42. Villar L., García-Barragán N., Espiño M., Roldán E., Sádaba M., Gómez-Rial J., González-Porqué P., Alvarez-Cermeño J. Influence of oligoclonal IgM specificity in multiple sclerosis disease course. Mult. Scler. 2008, 14:183-187.